Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

Arrowhead Pharmaceuticals  / Equity Bottom-Up

<ul><li>On November 18, 2025, Arrowhead Pharmaceuticals, Inc. (ARWR) announced that the U.S. Food and Drug Administration (FDA) approved REDEMPLO (plozasiran) for the treatment of adults with familial chylomicronemia syndrome (FCS).</li><li>Arrowhead has set a wholesale acquisition cost (WAC) for REDEMPLO of $60,000 per year.</li><li>This is approximately 1/10th of the cost of Tryngolza, although Ionis Pharmaceuticals has stated that if approved to treat severe hypertriglyceridemia (SHTG) the price of Tryngolza would be in the $10,000-$20,000/yr range.</li></ul>

On November 18, 2025, Arrowhead Pharmaceuticals, Inc. (ARWR) announced that the U.S. Food and Drug Administration (FDA) approved REDEMPLO (plozasiran) for the treatment of adults with familial chylomicronemia syndrome (FCS).Arrowhead has set a wholesale acquisition cost (WAC) for REDEMPLO of $60,000 per year.This is approximately 1/10th of the cost of Tryngolza, although Ionis Pharmaceuticals has stated that if approved to treat severe hypertriglyceridemia (SHTG) the price of Tryngolza would be in the $10,000-$20,000/yr range.

ARWR: REDEMPLO  Approved by FDA for the Treatment of FCS 